Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology

NCT ID: NCT04389541

Last Updated: 2023-08-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

499 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-04-17

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The retrospective cohort study INFINITY will be an instrument to analyze the current practice of precision oncology in the real-world setting. It will provide insight into real-world biomarker-directed treatment of cancer patients not eligible for standard therapies. The study will retrospectively collect medical records' data of patients who received a targeted treatment based on a potentially actionable alteration or biomarker identified by molecular diagnostics. Data of deceased patients will be included. The study will analyze how molecular test results guided clinical decision making. The compiled treatment and outcome data will be a valuable resource to analyze the use and effectiveness of targeted therapy approaches in biomarker-defined and entity-defined subpopulations of cancer patients. These signals might generate new insights and foster progress of targeted cancer treatment. The associated biomarker profiling module aims to set up a decentral biobank for future research on molecular alterations or central re-testing.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Solid Tumors or Hematologic Malignancies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Advanced solid tumors (i.e. locally advanced, inoperable and/or metastatic) or hematologic malignancies not eligible for standard therapy options (i.e. without further treatment options with drugs approved for the specific indication based on the judgement of the treating physician)
* Started or completed at the documenting study site a non-standard targeted therapy based on an actionable alteration or biomarker identified by molecular diagnostics
* Results on molecular diagnostics (e.g. tumor genomic or protein expression test) must be available; based on these results the therapy decision was taken
* Targeted therapy (given as monotherapy or as part of a therapy regimen) must be non-standard at time point of patient registration in the eCRF
* Age ≥ 18 years
* Signed and dated informed consent form (only if patient is alive at time of data entry into the project; not applicable for inclusion of deceased patients' data)

Exclusion Criteria

* Non-standard targeted therapy was given within a clinical trial
* The targeted therapy was given in a line of treatment for which it is non-standard (e.g. treatment in first line instead of second line where it is approved); the targeted therapy is however in principle approved for the given entity
* The targeted therapy was non-standard because a certain prior treatment has not been applied (e.g. targeted therapy is only approved after platin-based treatment but has been given without prior platin-based treatment); the targeted therapy is however in principle approved for the given entity
* The targeted therapy was non-standard because a different or no chemotherapy back-bone has been applied (e.g. targeted therapy is approved in combination with cisplatin but has been given with oxaliplatin or without chemotherapy backbone); the targeted therapy is however in principle approved for the given entity
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bristol-Myers Squibb

INDUSTRY

Sponsor Role collaborator

Roche Pharma AG

INDUSTRY

Sponsor Role collaborator

iOMEDICO AG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Norbert Marschner, MD

Role: PRINCIPAL_INVESTIGATOR

Outpatient center for hematology and oncology, Freiburg, Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

MVZ am Klinikum Aschaffenburg

Aschaffenburg, , Germany

Site Status

Studienzentrum Aschaffenburg

Aschaffenburg, , Germany

Site Status

Onkologische Schwerpunktpraxis

Augsburg, , Germany

Site Status

Hämatologisch-Onkologische Schwerpunktpraxis Bad Liebenwerda

Bad Liebenwerda, , Germany

Site Status

Sozialstiftung Bamberg Medizinisches Versorgungszentrum am Bruderwald gemeinnützige GmbH

Bamberg, , Germany

Site Status

Onkologische Schwerpunktpraxis Bamberg

Bamberg, , Germany

Site Status

Klinikum Bayreuth; Klinik für Onkologie und Hämatologie

Bayreuth, , Germany

Site Status

Onkologisches Versorgungszentrum Friedrichshain

Berlin, , Germany

Site Status

Onkologische Schwerpunktpraxis Kurfürstendamm

Berlin, , Germany

Site Status

Gemeinschaftspraxis für Onkologie und Hämatologie

Berlin, , Germany

Site Status

Evangelisches Waldkrankenhaus,Spandau,Innere Medizin I

Berlin, , Germany

Site Status

MVZ Onkologischer Schwerpunkt am Oskar-Helene-Heim

Berlin, , Germany

Site Status

Onkologisch-Hämatologische Schwerpunktpraxis

Bremen, , Germany

Site Status

Klinikum Coburg Hämatologie, Onkologie

Coburg, , Germany

Site Status

Schwerpunktpraxis für Hämatologie und internistische Onkologie Coburg

Coburg, , Germany

Site Status

PIOH - Praxis Internistische Onkologie und Hämatologie

Cologne, , Germany

Site Status

Gemeinschaftspraxis für Hämatologie und Onkologie, München MVZ GmbH

Cologne, , Germany

Site Status

Klinikum Darmstadt, Onkologisches Studienzentrum

Darmstadt, , Germany

Site Status

Onkologisches Zentrum Deggendorf

Deggendorf, , Germany

Site Status

Onkozentrum Dresden/Freiberg

Dresden, , Germany

Site Status

BAG / Onkologische Gemeinschaftspraxis

Dresden, , Germany

Site Status

Onkologische Gemeinschaftspraxis

Dresden, , Germany

Site Status

MVZ Onkologie und Hämatologie am Sana Krankenhaus Gerresheim

Düsseldorf, , Germany

Site Status

Praxis und Tagesklinik für gynäkologische Onkologie

Ebersberg, , Germany

Site Status

Studienbüro CHOP GmbH

Frankfurt a.M., , Germany

Site Status

Agaplesion Markus Krankenhaus

Frankfurt a.M., , Germany

Site Status

Universitätsklinikum Frankfurt; Medizinische Klinik 1: Pneumologie, Gastroenterologie, Hepatologie

Frankfurt a.M., , Germany

Site Status

Universitätsklinikum Frankfurt; Medizinische Klinik 2, Hämatologie, Onkologie

Frankfurt a.M., , Germany

Site Status

Praxis für interdisziplinäre Onkologie & Hämatologie

Freiburg im Breisgau, , Germany

Site Status

Gemeinschaftspraxis Panagiotou/Minaei (GbR)

Garbsen, , Germany

Site Status

MVZ II der Niels Stensen Kliniken Onkologie u. Hämatologie

Georgsmarienhütte, , Germany

Site Status

Gemeinschaftspraxis Dres. Schmitt und Eulenbruch

Gerlingen, , Germany

Site Status

Überörtliche Berufsausübungsgemeinschaft, MVZ Onkologische Kooperation Harz

Goslar, , Germany

Site Status

OSP Göttingen Dres. Meyer / Ammon / Metz

Göttingen, , Germany

Site Status

Gemeinschaftspraxis für Innere Medizin, Hämatologie, Onkologie, Gastroenterologie

Halle, , Germany

Site Status

Hämatologisch-Onkologische Praxis Eppendorf (HOPE)

Hamburg, , Germany

Site Status

Studiengesellschaft Hämato-Onkologie Hamburg Prof. Laack & Partner GbR

Hamburg, , Germany

Site Status

Hämatologisch-Onkologische Praxis Altona (HOPA)

Hamburg, , Germany

Site Status

Onkologische Schwerpunktpraxis

Hanover, , Germany

Site Status

MediProjekt GbR

Hanover, , Germany

Site Status

Gemeinschaftspraxis Dr. Haytham Kamal und Dr. David C. Dorn

Hanover, , Germany

Site Status

Onkologische Schwerpunktpraxis

Heidelberg, , Germany

Site Status

SLK Kliniken Heilbronn Klinik für Innere Medizin III

Heilbronn, , Germany

Site Status

Cancer Center Zweiseenland GbR

Herrsching am Ammersee, , Germany

Site Status

Onkologische Schwerpunktpraxis im Medicinum

Hildesheim, , Germany

Site Status

Onkologische Schwerpunktpraxis Dres. Hansen & Reeb

Kaiserslautern, , Germany

Site Status

Klinikum Kassel, Klinik für Onkologie und Hämatologie

Kassel, , Germany

Site Status

Internisten am Markt

Köthen, , Germany

Site Status

MVZ Hämatologie und Onkologie Dr. Michael Neise & Dr. André Lollert

Krefeld, , Germany

Site Status

ÜBAG - MVZ Dr. Vehling-Kaiser GmbH

Landshut, , Germany

Site Status

Gemeinschaftspraxis für Hämatologie und Onkologie GbR

Lebach, , Germany

Site Status

Onkologie UnterEms Leer-Emden-Papenburg

Leer, , Germany

Site Status

MVZ Mitte am Johannisplatz

Leipzig, , Germany

Site Status

Mannheimer Onkologie Praxis

Mannheim, , Germany

Site Status

Gemeinschaftspraxis für Hämatologie & Onkologie

Moers, , Germany

Site Status

Brustzentrum Niederrhein im evangelischen Krankenhaus Bethesda

Mönchengladbach, , Germany

Site Status

Praxis für Hämatologie, Onkologie & Palliativmedizin

Mönchengladbach, , Germany

Site Status

MVZ Onkologie GmbH am Elisabeth-Krankenhaus Rheydt

Mönchengladbach, , Germany

Site Status

Gemeinschaftspraxis für Hämatologie internistische Onkologie

Mülheim, , Germany

Site Status

Medizinisches Zentrum für Hämatologie und Onkologie

München, , Germany

Site Status

Hämatologisch-onkologische Gemeinschaftspraxis

Münster, , Germany

Site Status

Friedrich-Ebert-Krankenhaus

Neumünster, , Germany

Site Status

TZN - Tumorzentrum Niederrhein GmbH

Neuss, , Germany

Site Status

MVZ Onko Medical GmbH Neustadt Innere, Med./Hämatologie-Onkologie

Neustadt am Rübenberge, , Germany

Site Status

Internistische Praxis und Tagesklinik

Neustadt i.S., , Germany

Site Status

Onkologie Offenburg Ambulantes Therapiezentrum für Hämatologie und Onkologie

Offenburg, , Germany

Site Status

Pius-Hospital Oldenburg Hämatologie, Onkologie

Oldenburg, , Germany

Site Status

Onkologische Praxis Passau

Passau, , Germany

Site Status

Zentrum für Hämatologie und Onkologie MVZ GmbH

Porta Westfalica, , Germany

Site Status

MVZ für Blut- und Krebserkrankungen

Potsdam, , Germany

Site Status

Dr. Arnd Nusch

Ratingen, , Germany

Site Status

Studienzentrum Onkologie Ravensburg

Ravensburg, , Germany

Site Status

Praxis und Tagesklinik für Onkologie und Hämatologie

Recklinghausen, , Germany

Site Status

Schwerpunktpraxis und Tagesklinik für Hämatologie und Onkologie

Regensburg, , Germany

Site Status

Praxis und Tagesklinik für Onkologie und Hämatologie

Remscheid, , Germany

Site Status

Onkologische Praxis Remscheid

Remscheid, , Germany

Site Status

Schwerpunktpraxis im Ärztehaus Rheinbach

Rheinbach, , Germany

Site Status

Gemeinschaftspraxis für internistische Hämatologie und Onkologie

Rheine, , Germany

Site Status

Praxis für Hämatologie und Internistische Onkologie

Rostock, , Germany

Site Status

Klinikum Südstadt Rostock Innere Medizin III

Rostock, , Germany

Site Status

GPR Gesundheits- und Pflegezentrum Rüsselsheim

Rüsselsheim am Main, , Germany

Site Status

Zentrum Ambulante Onkologie

Schorndorf, , Germany

Site Status

Schwerpunktpraxis für Hämatologie und Internistische Onkologie, Gastroenterologie

Singen (Hohentwiel), , Germany

Site Status

MVZ Kloster Paradiese GbR

Soest, , Germany

Site Status

Hämatologie - Onkologie - Stolberg

Stolberg, , Germany

Site Status

Klinikum Stuttgart; Katharinenhospital Hämatologie, Onkologie und Palliativmedizin

Stuttgart, , Germany

Site Status

MVZ Leuschnerstr.

Stuttgart, , Germany

Site Status

Kliniken Südostbayern - Klinikum Traunstein

Traunstein, , Germany

Site Status

Praxisnetzwerk Hämatologie / internistische Onkologie

Troisdorf, , Germany

Site Status

Onkologie Schwarzwald-Alb Dr. med. G. Köchling

Villingen-Schwenningen, , Germany

Site Status

Praxen MVZ für Innere Medizin

Weinheim, , Germany

Site Status

Gemeinschaftspraxis für Hämatologie und Onkologie

Westerstede, , Germany

Site Status

Praxisgemeinschaft für Onkologie und Urologie

Wilhelmshaven, , Germany

Site Status

Internistische Gemeinschaftspraxis,Hämatologie, Onkologie,Palliativmedizin

Worms, , Germany

Site Status

MVZ West GmbH Würselen Hämatologie-Onkologie

Würselen, , Germany

Site Status

Hämatologisch-Onkologische, Schwerpunktpraxis Würzburg GbR,Dres. med. R. Schlag & B. Schöttker

Würzburg, , Germany

Site Status

Praxis und Tagesklinik für Hämatologie/Onkologie

Zittau, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Martens UM, Schroder J, Bengsch F, Sellmann L, Busies S, Frank-Gleich S, Zaiss M, Decker T, Schneeweiss A, Schuler M, Grebhardt S, Zacharias S, Marschner N, Kasenda B, Potthoff K, Vannier C. The INFINITY study protocol: a retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice. BMC Cancer. 2023 Jun 13;23(1):543. doi: 10.1186/s12885-023-11046-3.

Reference Type DERIVED
PMID: 37312086 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IOM-050408

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors
NCT05990452 ACTIVE_NOT_RECRUITING PHASE1/PHASE2
SG2918 For Advanced Malignant Tumors
NCT06167486 RECRUITING PHASE1